The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of maximal ablative irradiation because of encasement (MAIBE) for patients with potentially resectable locally advanced pancreatic cancer.
 
Marsha Reyngold
Research Funding - Elekta MRL Consortium
 
Wei Alice
Honoraria - AstraZeneca Canada; Medtronic
Consulting or Advisory Role - Biosapien; Histosonics
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Adicet Bio (I); Alnylam (I); AstraZeneca; Autem Medical (I); BeiGene (I); Berry Genomics (I); BioSapien; BioSapien; Boehringer Ingelheim; Cend Therapeutics; CytomX Therapeutics; CytomX Therapeutics; Eisai (I); Exelixis (I); Flatiron Health (I); Genentech/Roche (I); Genoscience Pharma (I); Helio Health (I); IDEAYA Biosciences; Incyte (I); Ipsen; Legend Biotech (I); Merck; Nerviano Medical Sciences (I); Novartis; Noxxon Pharma; QED Therapeutics (I); Rafael Pharmaceuticals; RedHill Biopharma (I); Seagen; Thetis Pharma; Yiviva (I)
Research Funding - Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Celgene (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Parker Institute for Cancer Immunotherapy (Inst); Roche (Inst); Silenseed (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma
 
Michael Ian D'Angelica
No Relationships to Disclose
 
Jeffrey A. Drebin
Employment - American Regent (I)
Leadership - American Regent (I)
Stock and Other Ownership Interests - Alnylam; Arrowhead Pharmaceuticals; Ions Pharmaceuticals
 
Kevin Soares
No Relationships to Disclose
 
T. Peter Kingham
No Relationships to Disclose
 
Vinod P. Balachandran
Research Funding - Genentech/Roche (Inst)
Patents, Royalties, Other Intellectual Property - Inventors on a patent application related to work on antigen cross-reactivity and on a patent application related to work on neoantigen quality modeling.
 
Anna M. Varghese
Consulting or Advisory Role - Lilly (I); Roche (I)
Research Funding - BioMed Valley Discoveries; Bristol-Myers Squibb; Illumina (I); Lilly; Silenseed; Verastem
Travel, Accommodations, Expenses - Roche (I)
 
Wungki Park
Consulting or Advisory Role - Aegle; onconic therapeutics
Research Funding - Astellas Pharma (Inst); Gossamer Bio (Inst); Merck (Inst)
 
Danny Khalil
Consulting or Advisory Role - Abbvie; PsiOxus Therapeutics
Research Funding - Merck (Inst)
Patents, Royalties, Other Intellectual Property - Intellectual property interests related to CD40, nanotechnology, and in situ vaccination.
 
Kenneth H. Yu
Consulting or Advisory Role - Ipsen
Research Funding - General Oncology (Inst); Ipsen; OncoC4 (Inst); Senhwa Biosciences (Inst)
 
Melissa Zinovoy
No Relationships to Disclose
 
John J Cuaron
No Relationships to Disclose
 
Carla Hajj
No Relationships to Disclose
 
Paul Bernard Romesser
Consulting or Advisory Role - EMD Serono; Faeth Therapeutics; Natera
Research Funding - X-RAD Therapeutics
Travel, Accommodations, Expenses - Elekta
 
Abraham Jing-Ching Wu
Stock and Other Ownership Interests - Simphotek
Consulting or Advisory Role - AstraZeneca; MORE Health; NanoVi
Research Funding - CivaTech Oncology
Travel, Accommodations, Expenses - CivaTech Oncology
 
Zhigang Zhang
No Relationships to Disclose
 
William R. Jarnagin
No Relationships to Disclose
 
Christopher H. Crane
Stock and Other Ownership Interests - Oncternal Therapeutics
Honoraria - Elekta
Consulting or Advisory Role - TriSalus Life Sciences
Research Funding - Elekta (Inst)